EGb 761

Drug Profile

EGb 761

Alternative Names: GBE 761; Gingogink; Ginkgo biloba special extract - Dr Wilmar Schwabe Group/Ipsen; Tanakan; Tebonin; Tramisal

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Dr. Willmar Schwabe Pharmaceuticals
  • Developer Dr. Willmar Schwabe Pharmaceuticals; Ipsen
  • Class Antiplatelets; Herbal medicines; Phytotherapies
  • Mechanism of Action Antioxidants; Nitric oxide synthase type II inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alzheimer's disease; Cognition disorders; Ear disorders; Eye disorders; Neurological disorders; Vascular disorders
  • Phase III Tinnitus
  • Phase II Vertigo
  • No development reported Friedreich's ataxia
  • Discontinued Pancreatic cancer

Most Recent Events

  • 17 Sep 2016 Phase-II clinical trials in Vertigo in Poland (PO, Tablet) (ISCRTN83227991; EudraCT2016-000316-15)
  • 02 Sep 2016 Phase-II clinical trials in Tinnitus in Poland (PO) (EudraCT2016-000315-32)
  • 28 Jul 2016 Launched for Neurological disorders (Combination therapy) in Russia before July 2016 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top